State Of Wisconsin Investment Board Inhibrx, Inc. Transaction History

State Of Wisconsin Investment Board

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$32.76 - $39.56 $821,948 - $992,560	-25,090 Reduced 57.08%	18,866 $659,000
Q4 2023 Feb 12, 2024	SELL	$14.5 - $38.0 $129,427 - $339,188	-8,926 Reduced 16.88%	43,956 $1.67 Million
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $369,825 - $617,785	23,481 Added 79.86%	52,882 $970,000
Q2 2023 Aug 14, 2023	SELL	$16.96 - $27.82 $10,650 - $17,470	-628 Reduced 2.09%	29,401 $763,000
Q1 2023 May 15, 2023	BUY	$18.45 - $27.14 $149,574 - $220,023	8,107 Added 36.98%	30,029 $566,000
Q4 2022 Feb 14, 2023	SELL	$20.18 - $33.33 $29,261 - $48,328	-1,450 Reduced 6.2%	21,922 $540,000
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $116,714 - $249,253	10,079 Added 75.82%	23,372 $420,000
Q2 2022 Aug 15, 2022	SELL	$8.52 - $25.26 $193,463 - $573,578	-22,707 Reduced 63.08%	13,293 $151,000
Q3 2021 Nov 12, 2021	BUY	$25.18 - $37.81 $24,827 - $37,280	986 Added 2.82%	36,000 $1.2 Million
Q2 2021 Aug 12, 2021	BUY	$14.69 - $27.52 $514,355 - $963,585	35,014 New	35,014 $964,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $580M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

Stay updated on State Of Wisconsin Investment Board with notifications on news.